[Endocrinological aspects of fibrocystic mastopathy].
D000328:Adult; D000818:Animals; D001284:Atrophy / Q000175:diagnosis; D001940:Breast / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D001941:Breast Diseases / Q000503:physiopathology*; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004108:Dilatation, Pathologic / Q000175:diagnosis; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000502:physiology; D005260:Female; D005348:Fibrocystic Breast Disease / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D045167:Progesterone Congeners / Q000627:therapeutic use; D011388:Prolactin / Q000037:antagonists & inhibitors; D012306:Risk
D003278:Contraceptives, Oral, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D045167:Progesterone Congeners; D011388:Prolactin; D003613:Danazol
Aspetti endocrinologici della mastopatia fibrocistica.